Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 87

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 87
---
, then Nasdaq will notify us of its determination to delist our common stock, at which point we will
have an opportunity to appeal the delisting determination to a Hearings Panel.

No
assurance can be given that we will be able to regain compliance with the Rule. Failure to meet applicable Nasdaq continued listing standards
could result in a delisting of our common stock. A delisting of our common stock from Nasdaq could materially reduce the liquidity of
our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm
our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential
loss of confidence by investors, employees and fewer business development opportunities.

The
market price of our common stock is volatile and you may sustain a complete loss of your investment.

Our
common stock currently trades on the Nasdaq Capital Market. The market price of our common stock has been, and is likely to continue
to be, volatile. The market price of our common stock may fluctuate significantly in response to numerous factors, some of which are
beyond our control, such as:

    ●
    inability
    to obtain the approvals necessary to commence clinical trials;

    ●
    results
    of clinical and preclinical studies;

    ●
    announcements
    of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes
    or delays in the regulatory review process;

    ●
    announcements
    of technological innovations, new products or product enhancements by us or others;

    ●
    adverse
    actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;

    ●
    changes
    or developments in laws, regulations or decisions applicable to our product candidates or patents;

    ●
    any
    adverse changes to our relationship with manufacturers, suppliers or partners;

    ●
    announcements
    concerning our competitors or the pharmaceutical or biotechnology industries in general;

57

    ●
    achievement
    of expected product sales and profitability or our failure to meet expectations;

    ●
    our
    commencement of or results of, or involvement in, litigation, including, but not limited to, any product liability actions or intellectual
    property infringement actions;

    ●
    any
    major changes in our board of directors, management or other key personnel;

    ●